Peptide of the Week: Retatrutide's Phase 3 Data Lands — And So Does a Delay
By PeptideChat Team · July 28, 2026
Retatrutide has been the most-discussed unapproved compound in the peptide world for two years, largely on the strength of phase 2 data and a lot of extrapolation. As of this summer, we finally have the real thing: three phase 3 trials, thousands of participants, and a full adverse-event profile.
The short version — the efficacy is genuinely historic, the tolerability is not free, and the compound is now further from approval than people expected six months ago.
What Retatrutide Is
Retatrutide is a triple agonist: it activates the GLP-1, GIP, and glucagon receptors in a single weekly injection. The first two are the tirzepatide combination. The third — glucagon — is the differentiator, and it is thought to contribute to energy expenditure rather than appetite suppression alone. That mechanistic addition is the entire thesis behind why retatrutide might outperform the dual agonists.
TRIUMPH-1: The Headline Numbers
TRIUMPH-1 randomized 2,339 participants 1:1:1:1 to retatrutide 4 mg, 9 mg, 12 mg, or placebo for 80 weeks, from a baseline weight of roughly 112.7 kg (248.5 lb).
At the 80-week primary endpoint:
| Dose | Average weight loss |
|---|---|
| 4 mg | −19.0% (−47.2 lb) |
| 9 mg | −25.9% (−64.4 lb) |
| 12 mg | −28.3% (−70.3 lb) |
| Placebo | −2.2% (−5.5 lb) |
28.3% is the largest average weight loss recorded in a phase 3 obesity trial. At the top dose, 45.3% of participants lost at least 30% of their body weight, against 0.5% on placebo, and 65.3% reached a BMI under 30. Those are extraordinary figures by any standard.
About That "30.3%" Number
You will see −30.3% quoted widely. It is real, but it is not the primary endpoint, and it is worth understanding before you repeat it.
A pre-specified extension enrolled 532 participants — only those with a baseline BMI of 35 or above who had tolerated their dose — and continued to 104 weeks. That subgroup on 12 mg reached −30.3% (−85.0 lb).
Here is the part that gets misreported. The extension's placebo row reads −19.2%, which would be an absurd placebo response. It isn't one: those participants were switched onto active drug at their maximum tolerated dose during the extension. There was no true placebo arm at 104 weeks. If you see −19.2% cited as "the placebo group," the source has misread the table.
The defensible headline number is −28.3% at 80 weeks.
The Cost Side
Retatrutide's adverse-event profile is where the enthusiasm needs tempering. Against placebo:
- Nausea: 28.6-42.4% (vs 14.8%)
- Diarrhea: 25.2-34.1% (vs 13.5%)
- Constipation: 23.8-26.1% (vs 10.9%)
Most consequential is discontinuation due to adverse events, which was dose-dependent: 4.1% at 4 mg, 6.9% at 9 mg, and 11.3% at 12 mg, against 4.9% on placebo. At the dose that produces the headline weight loss, roughly one in nine participants stopped because they could not tolerate it — more than double the placebo rate.
Two signals also appeared that are not part of the familiar GLP-1 picture: dysesthesia (abnormal or unpleasant sensation, reported in roughly 5-12.5% of participants, rising with dose) and an increase in urinary tract infections. Dysesthesia in particular is a newer class observation and deserves attention rather than a footnote.
The Numbers Drop in Sicker Populations
TRIUMPH-1 enrolled people with obesity but without diabetes. The companion trials tell a more moderate story:
- TRIUMPH-2 (type 2 diabetes): roughly 21% weight loss at 80 weeks
- TRIUMPH-3 (established cardiovascular disease): roughly 23%
Still excellent — but 5 to 7 percentage points below the headline, and closer to where most real-world patients actually sit. In TRIUMPH-3, three-point MACE events were 27 on retatrutide versus 23 on placebo; a five-point composite numerically favored retatrutide. Cardiovascular outcomes will need a dedicated trial to interpret properly.
The Delay
On July 23, 2026, alongside the TRIUMPH-2 and -3 results, Lilly announced its FDA submission is moving to Q1 2027, citing additional time needed for manufacturing and quality-control data. The prior expectation had been end of 2026.
Filing in early 2027 realistically means approval no earlier than late 2027, and plausibly 2028.
Why This Matters for Anyone Watching the Gray Market
Retatrutide is not approved anywhere in the world. It also cannot be legally compounded in the US, because compounding law requires a substance to be a component of an approved drug — and retatrutide isn't one. There is no legitimate pharmacy channel for it at any price. Everything currently circulating is unregulated, and the delay means that stays true for another eighteen months at minimum.
We wrote separately about what that unregulated supply actually looks like — including a certificate of analysis that appeared to describe a different drug entirely. That piece is worth reading alongside this one.
The Takeaway
Retatrutide's phase 3 program delivered the best weight-loss efficacy ever recorded in a trial of this size, with a real tolerability cost at the top dose and a meaningfully lower ceiling in people with diabetes or cardiovascular disease. The science lived up to the hype. The timeline did not — approval is now a 2027-2028 question.
This article is for research and educational purposes only. It is not medical advice, and it does not endorse the purchase or use of any compound. Retatrutide is an investigational compound that is not approved for human use in any country.